Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership

Executive Summary

• Kane Biotech announced a distribution agreement with Marathon Medical Corporation, giving the company access to U.S. Veterans Affairs, Department of Defense and Indian Health Services procurement channels.
• The Company is also signing multiple independent sales‑representative agreements and building a contract‑based national sales team throughout 2026.
• These steps are positioned as a key milestone toward establishing revyve® as a nationwide brand in advanced wound care.

Key Details

• Distribution Agreement: Signed with Marathon Medical Corp., a federally verified Service‑Disabled Veteran‑Owned Small Business (SDVOSB) and national medical‑supply distributor.
• Target Markets: U.S. Veterans Affairs (VA), Department of Defense (DoD), and Indian Health Services (IHS).
• Strategic Benefit: Leverages Marathon’s existing federal procurement contracts, streamlining purchasing, logistics and product onboarding for revyve wound‑care products.
• Sales Force Expansion: Kane is building a contract‑based sales team with members already in place across the U.S.; additional hires planned throughout 2026.
• Product Portfolio Covered: FDA 510(k) cleared revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray (both also Health Canada approved).
• Leadership Quote: Interim CEO Dr. Robert Huizinga highlighted the partnership as “an essential step in making revyve accessible to veterans, active service members and indigenous peoples.”

Notable Quotes

“We are continuing to strategically build the commercial infrastructure required to make revyve a national brand in advanced wound care,” – Interim CEO Dr. Robert Huizinga
“Our new contract‑based sales agents expand our reach into key markets, while our partnership with Marathon Medical gives us a powerful foothold within the U.S. government system—an essential step in making revyve accessible to the veterans, active service members and indigenous peoples.” – Interim CEO Dr. Robert Huizinga